Hologic and Bayer Partner to Improve Mammography Imaging

Contrast-enhanced mammography (CEM) is an effective and relatively affordable imaging method for diagnosing breast cancer and guiding treatment options. It involves the use of digital mammography along with a contrast agent. Its utility as a supplement to standard mammography is supported by a growing body of independent research. CEM can be incorporated into routine clinical care and is versatile, being useful in different scenarios such as when previous imaging results are inconclusive, for pre-surgical evaluation of disease extent, or when MRI is not an option. To advance the capabilities of CEM, an international partnership aims to offer enhanced CEM solutions for women in various countries, spanning Europe, Canada, and the Asia Pacific regions.

Hologic Inc. (Marlborough, MA, USA) and Bayer (Leverkusen, Germany) have entered into an international partnership to bring together their pioneering technologies. Hologic will provide its advanced mammography gantries, while Bayer will contribute its CEM-approved injection systems. This partnership is designed to fully equip radiologists and their medical staff with a complete package of products and the necessary training to effectively incorporate CEM into their existing operations.

“Over the past several years, we’ve seen an increased interest in contrast-enhanced mammography as an additional diagnostic modality. Our partnership with Bayer will enable clinicians around the world to offer CEM as part of the breast cancer diagnostic workflow,” said Tanja Brycker, Vice President of strategic Development, Breast and Skeletal Health and GYN Solutions at Hologic. “As one of the world leaders in mammography and women’s health, we are committed to enabling healthier lives everywhere, every day. By increasing access to additional breast imaging technology to women across the globe, our international partnership with Bayer is a compelling example of that commitment in action.”

“Breast cancer is the world’s most prevalent cancer, impacting millions of women and their loved ones around the globe,” said Gerd Krueger, President of Radiology at Bayer. “Accurate and timely detection is crucial to improve patient outcomes and save patients’ lives. We are excited to join forces with Hologic to deliver a comprehensive solution to our customers and increase access to an emerging breast imaging modality that can help improve diagnostic accuracy as well as provide an alternative imaging option for many women who need it.”

Related Links:
Hologic Inc.
Bayer